Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
As a part of the royalty agreement, Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a combination therapy indication for the compound.
